CARsgen Announces CT041 Granted RMAT Designation by the FDA
CARsgen Therapeutics Holdings Limited, a company primarily focused on developing novel CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announced today that CT041 h ...